Business Areas
Improving the quality of our lives through state-of-the-art R&D capabilities.
Life science, with outstanding R&D competence and new drugs that have been approved by USFDA for the first time in Korea, is LG Chem’s new growth engine in the mid to long term.
We are aggressively making inroads in overseas markets and expanding pipelines for new drugs through constant investment and reinforcing R&D, with aspirations to become one of the top global pharmaceutical companies.
Sales

Unit : KRW trillion

  • 1961 Obtained the drug manufacturing permit
  • 1984 Established Pharmaceuticals
    business division
  • 1991 Developed World’s first
    4th generation Cephalosporin
  • 1996 Won the first prequalification by the WHO with Hepatitis B vaccine Euvax B
  • 2003 1st Korean NCE approved by
    USA FDA(Factive)
  • 2012 Released the first Korean diabetes drug Zemiglo
  • 2017 Merged with
    LG Life Sciences
  • 2019 Established the Global Innovation Center in Boston, US
  • 2021 Established a joint venture sales corporation LG Jiansheng Life Sciences in ChinaSucceeded in phase II clinical trial of the new gout drug in the US
  • 2022 Applied for global Phase lll clinical trial for Tigulixostat(new dug for gout) with the US
Division
Primary Care Division Primary Care Division
Specialty Care Division Specialty Care Division
Aesthetic Division Aesthetic Division
Go to the related products ▶
VISION

Toward a World-Class Innovative Drug Developer

  • 2 or more innovative New drugs by 2030
  • · First-rate pipelines in Korea
  • · Invest over USD 250mil in annual R&D
  • · Open Innovation
  • Diabetes, metabolic diseases, Cancer, autoimmune diseases
  • Expand new drug pipelines in clinical development stage
  • Accelerate clinical development and business growth worldwide
  • · Reinforcing talent pool of clinical/regulatory specialists
  • · Increase overseas sales by 50%
LG Chem Life Science Pipeline

As of August 2023

  • Aesthetic
  • Cell Therapy
  • Diabetes & Metabolism
  • Oncology & Immunology
  • Vaccine
  1. Preclinical (8)
    • LR19131

      NASH
      LR19131
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication NASH
      Modality NCE
      Target Undisclosed
      Partner -
    • LR19025

      Osteoarthritis
      LR19025
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Osteoarthritis
      Modality Cell therapy
      Target Undisclosed
      Partner Medipost
    • LR19023

      Oncology
      LR19023
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
      Partner -
    • LR22011

      Oncology
      LR22011
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Cell therapy
      Target Undisclosed
      Partner -
    • LR20009

      Oncology
      LR20009
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality NCE
      Target Undisclosed
      Partner -
    • LR19128

      Oncology
      LR19128
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner Avactar Life sciences

      Affimer® Technology

    • LR19155

      Oncology
      LR19155
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication Oncology
      Modality Biologics
      Target Undisclosed
      Partner -
    • LR20008

      HA filler
      LR20008
      해당 프로젝트 팝업
      Molecule -
      Stage Preclinical
      Indication HA filler
      Modality HA
      Target HA
      Partner -
  2. Phase I (12)
    • LR19129

      CUE-102
      Oncology
      LR19129
      해당 프로젝트 팝업
      Molecule CUE-102
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target WT-1
      Partner Cue Biopharma
    • LR19127

      CUE-101
      Oncology
      LR19127
      해당 프로젝트 팝업
      Molecule CUE-101
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication HNSCC
      Modality Biologics
      Target HPV
      Partner Cue Biopharma
    • LR19125

      PDC*Lung
      Oncology
      LR19125
      해당 프로젝트 팝업
      Molecule PDC*Lung
      Stage Phase 1
      (by Partner)
      Location summary Europe
      Indication NSCLC
      Modality Cell therapy
      Target Cancer vaccine
      Partner PDC*line Pharma
    • LR20011

      GEN-001
      Oncology
      LR20011
      해당 프로젝트 팝업
      Molecule GEN-001
      Stage Phase 1
      (by Partner)
      Location summary USA
      Indication Solid tumor
      Modality Microbiome
      Target Microbiome
      Partner Genome & Company
    • LR21004

      BLR21004
      Osteoarthritis
      LR21004
      해당 프로젝트 팝업
      Molecule BLR21004
      Stage Phase 1
      (by Partner)
      Location summary Australia
      Indication Osteoarthritis
      Modality Gene therapy
      Target Nkx3.2/AAV
      Partner ICM
    • AV-380

      AV-380
      Oncology
      AV-380
      해당 프로젝트 팝업
      Molecule AV-380
      Stage Phase 1
      Location summary USA
      Indication Cachexia
      Modality Biologics
      Target anti-GDF15 IgG1 mAb
      Partner -
    • AV-203

      Oncology
      AV-203
      해당 프로젝트 팝업
      Molecule AV-203
      Stage Phase 1
      Location summary USA
      Indication Oncology
      Modality Biologics
      Target Anti-ERBB3
      IgG1 mAb
      Partner -
    • LR19021

      LB54640
      Genetic Obesity
      LR19021
      해당 프로젝트 팝업
      Molecule LB54640
      Stage Phase 1
      Location summary USA
      Indication Genetic Obesity
      Modality NCE
      Target MC4R
      Partner -
    • LR20056

      LG303174
      NASH
      LR20056
      해당 프로젝트 팝업
      Molecule LG303174
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target VAP-1
      Partner TransThera
    • LR19123

      LC542019
      Diabetes
      LR19123
      해당 프로젝트 팝업
      Molecule LC542019
      Stage Phase 1
      Location summary USA
      Indication Diabetes
      Modality NCE
      Target GPR120
      Partner -
    • LR19018

      LG203003
      NASH
      LR19018
      해당 프로젝트 팝업
      Molecule LG203003
      Stage Phase 1
      Location summary USA
      Indication NASH
      Modality NCE
      Target DGAT-2
      Partner -
    • LR20062

      aP 6 in 1 Vaccine
      LR20062
      해당 프로젝트 팝업
      Molecule aP vaccine
      Stage Phase 1
      Indication aP vaccine
      Modality Vaccine
      Target aP vaccine
      Partner -
  3. Phase II (4)
    • LR19114

      6 in 1 Vaccine
      LR19114
      해당 프로젝트 팝업
      Molecule 6 in 1 Vaccine
      Stage Phase 2
      Indication 6 in 1 Vaccine
      Modality Vaccine
      Target 6 in 1 Vaccine
      Partner -

      Diphtheriae (D), Bordetella pertussis (wP),

      Clostridium tetani (T), Hepatitis B (HepB)

      Haemophilus influenzae type b(Hib)

      Vaccine-Associated Paralytic Poliomyelitis(IPV)

    • LR19019

      Zectivimod
      Atopic Dermititis
      LR19019
      해당 프로젝트 팝업
      Molecule Zectivimod
      Synonyms:LC510255
      Stage Phase 2
      (by Partner)
      Location summary China
      Indication Ulcerative colitis
      Atopic dermatitis
      Modality NCE
      Target S1P1
      Partner TransThera
      (License-out)

      License-out, China

    • LR19024

      LG34053
      Osteoarthritis
      LR19024
      해당 프로젝트 팝업
      Molecule LG34053
      Stage Phase 1b/2
      Location summary Republic of Korea
      Indication Osteoarthritis
      Modality NCE
      Target Undisclosed
      Partner -
    • AV-299

      Ficlatuzumab
      Oncology
      AV-299
      해당 프로젝트 팝업
      Molecule Ficlatuzumab
      Stage Phase 2
      Location summary USA
      Indication Head and neck squamous cell carcinoma
      Modality Biologics
      Target Anti-HGF/c-MET
      IgG1 mAb
      Partner -
  4. Phase III (6)
    • LR19074

      Tigulixostat
      Gout
      LR19074
      해당 프로젝트 팝업
      Molecule Tigulixostat
      Synonyms:LC350189
      Stage Phase 3
      Indication Gout
      Modality NCE
      Target XO
      Xanthine Oxidate
      Partner -

      Clinical trials

      https://clinicaltrials.gov/ct2/show/NCT03934099?term=LC350189&draw=2&rank=7

    • LR20023

      Botulinum Toxin
      LR20023
      해당 프로젝트 팝업
      Molecule Botulinum toxin
      Stage Phase 3
      Location summary Republic of Korea
      Indication Botulinum toxin
      Modality Botulinum toxin
      Target Botulinum toxin
      Partner Pharma Research Bio
    • LR19094

      Y-solution, China
      HA Filler
      LR19094
      해당 프로젝트 팝업
      Molecule Y-solution, China
      Stage Phase 3
      Location summary China
      Indication HA filler
      Modality HA
      Target HA
      Partner -
    • LR20024

      Y-solution, MDR
      HA Filler
      LR20024
      해당 프로젝트 팝업
      Molecule Y-solution, MDR
      Stage Phase 3
      Location summary Europe
      Indication HA filler
      Modality HA
      Target HA
      Partner -
    • FOTIVDA® +/- OPDIVO®

      Tivozanib
      Oncology
      FOTIVDA® +/- OPDIVO®
      해당 프로젝트 팝업
      Molecule Tivozanib +/- Nivolumab
      Stage Phase 3
      Location summary Global
      Indication Renal Cell Carcinoma following prior CPI
      Modality Small molecule
      Target VEGFR TKI
      Partner Bristol Myers Squibb
      Opdivo combination
    • FOTIVDA® + IMFINZI®

      Tivozanib
      Oncology
      FOTIVDA® + IMFINZI®
      해당 프로젝트 팝업
      Molecule Tivozanib + Durvalumab
      Stage Phase 3
      Location summary USA
      Indication Hepatocellular Carcinoma
      Modality Small molecule
      Target Target” VEGFR TKI
      Partner AstraZeneca, Imfinzi combination
  5. NDA (0)
Image Download 다운로드
Core Products
Eutropin Eutropin
Hyruan One Hyruan One
Zemiglo Zemimet SR Tab Zemiglo Zemimet SR Tab
Eucept Eucept
YVOIRE YVOIRE
Press Releases
LG Chem to expand overseas infertility treatment business 2023.09.22
LG Chem to expand overseas infertility treatment business 2023.09.22
LG Chem to expand overseas infertility treatment business 2023.09.22
more
Video
Select Opening of a Global Innovation Center Opening of a Global Innovation Center